Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference

MYSTIC, Conn. and DUBLIN, Dec. 3, 2010 /PRNewswire-FirstCall/ —
Amarin Corporation plc (Nasdaq:
AMRN) today announced that it is scheduled to present at the
Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity
Conference on Tuesday, December 7, 2010 at 3:00pm PST. The
conference will be held at the Nikko Hotel in San Francisco.

A live audio webcast of the presentation will be available at
the following URL:  

http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3331020

About AmarinAmarin Corporation plc is a clinical-stage
biopharmaceutical company with expertise in lipid science focused
on the treatment of cardiovascular disease. The Company’s lead
product candidate is AMR101 (ethyl icosapentate).On November 29,
2010, the Company reported positive, statistically significant
top-line results from the MARINE trial, the first of its Phase 3
clinical trials of AMR101. In the MARINE trial, AMR101 was
investigated as a treatment for very high triglycerides(>500
mg/dL). AMR101 is presently being investigated in a second Phase 3
clinical trial, the ANCHOR trial, for the treatment of patients on
statin therapy with high triglycerides (≥200 and <500mg/dL)
with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial
currently is, conducted under Special Protocol Assessment (SPA)
agreements with the U.S. Food and Drug Administration (FDA).
Amarin also has next-generation lipid candidates under evaluation
for preclinical development. For more information, including a
summary of MARINE trial top-line results, please visit www.amarincorp.com.Investor
Contact Information: John F. Thero President In U.S.: +1 (860)
572-4979
investor.relations@amarincorp.

‘/>”/>

SOURCE